AKT1 and hepatocellular carcinoma: Sorafenib upregulates ABCC5 via the PI3K/Akt/Nrf2 pathway, which inhibits lipid peroxidation-mediated ferroptosis and promotes cancer growth, resulting in acquired sorafenib resistance in human HCC cells, according to Huang et al (91).